The commercial function isn't just marketing. Its critical purpose is to ensure the healthcare delivery system is equipped to receive a new therapy. A great product is merely "table stakes"; adoption hinges on overcoming systemic barriers between regulatory approval and actual patient access.

Many firms view patient engagement as a compliance task that adds cost. However, data shows integrating patient experience into development from the start speeds up clinical trial recruitment and execution, reduces FDA amendments, and accelerates time-to-market, providing clear ROI.

Genentech tackles affordability with a multi-pronged approach beyond pricing. They provide a call center to help patients navigate insurance, offer free medicine through a foundation, and re-engineer drugs for at-home administration, aiming to shift 75% of their portfolio out of hospital settings and into patients' living rooms.

Instead of a fragmented 'kitchen sink' approach, pharmaceutical companies should first deeply understand patient pain points. This understanding then guides the selection and coordination of various specialized vendors, ensuring a seamless and effective support system that avoids overwhelming the patient.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Healthcare systems invest heavily in diagnosis but then abandon patients once a prescription is handed over. This "disconnection point" leads to medication non-adherence and confusion, as the patient's actual healing journey is just beginning and requires ongoing support.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

Walgreens prioritizes tackling barriers to medication access—such as cost and prior authorizations—believing that adherence can only be addressed once a patient can consistently obtain their therapy. This frames the two issues as a sequence, not parallel challenges.